Role of DEPTOR in T Cell Activation and Alloimmunity
Role of DEPTOR in T Cell Activation and Alloimmunity
批准号:
10062851
负责人:
David M. Briscoe
金额:
$70.8万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-12-08 至 2022-11-30
关键词:
AcuteAddressAllograftingAntigensAreaBiologicalBiological Response Modifier TherapyBiologyCD4 Positive T LymphocytesCell CommunicationCell Differentiation processCell physiologyCellsCellular Metabolic ProcessChronicDevelopmentDiseaseEragrostisExcisionFOXP3 geneFRAP1 geneFundingGraft RejectionGraft SurvivalImmuneImmunobiologyIn VitroIndividualIntrinsic factorKnock-in MouseKnockout MiceLifeLinkLiteratureMetabolic PathwayMetabolismModelingNormal CellOrgan TransplantationOutcomePathologicPharmacologyPhenotypePhysiologicalPreventionProcessRegulationRegulatory T-LymphocyteResearchResearch ProposalsRoleSavingsSignal TransductionSirolimusT cell differentiationT-Cell ActivationT-Lymphocyte SubsetsTestingTherapeuticTransgenic MiceTransgenic OrganismsTransplantationUbiquitinationVascular Endothelial Cellallograft rejectioncancer cellcell typeclinically relevantcohesioneffector T cellend-stage organ failurefunctional outcomesgenetic regulatory proteinimmunoregulationin vivoin vivo Modelinhibitor/antagonistinnovationinsightisoimmunitymTOR Inhibitornoveloverexpressionpreventresponsesmall moleculetransplant model
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
Allograft rejection is characterized by effector CD4+ T cell activation in response to donor antigen and an
intense cellular and humoral attack on the graft. However, multiple intracellular signals within CD4+ T cells
operate co-incidentally to enhance the expansion and function of CD4+Foxp3+ T regulatory cells that
collectively serve to control the alloimmune response. Furthermore, the potency of this process of
immunoregulation prevents and restrains alloimmune T effector cell activation and rejection. Importantly,
recent advances indicate that CD4+Foxp3+ T cell differentiation and function is negatively regulated by the
cell intrinsic activity of mTOR and specifically mTORC1. However, little is known about the regulation of
intracellular mTOR signaling within alloreactive CD4+ T cell effectors, or how its relative activity may be
modulated in Foxp3+ subsets, or whether it is possible to exploit modulatory signals to augment
physiological Treg activity in pathological states to prevent disease, including the development of chronic
allograft rejection. DEPTOR is a recently discovered cell intrinsic factor that modulates mTOR-induced
signaling responses in highly proliferative cancer cells, and it has more recently been observed to function
in normal cell types including vascular endothelial cells. In preliminary studies, we find that DEPTOR is
expressed at high levels in unactivated CD4+ T cells, and further, that its expression is reduced upon
cellular activation. In addition, we find that forced overexpression of DEPTOR modulates CD4+ T cell
activation responses in vitro, promotes immunoregulation and prolongs graft survival following fully MHC
mismatched transplantation in vivo. We suggest that these observations identify DEPTOR as a critical
upstream intracellular modulator of CD4+ T cell activation as well as the phenotypic and functional outcome
of the alloimmune response. Our objectives in this R01 are to further evaluate these observations using
novel transgenic mice, and 1), define the select function of DEPTOR in CD4+ T effector and regulatory
subsets in vivo, and 2), evaluate the consequences of CD4+ T cell DEPTOR expression in models of
transplant rejection. We will test the hypothesis that DEPTOR is a cell intrinsic molecule that modulates
CD4+ T effector cell activation and augments CD4+ T regulatory cell function to enhance immunoregulation
and promote long-term graft survival. We propose two specific aims in which we will: 1), determine the
consequences and mechanism of function of cell intrinsic DEPTOR in CD4+ T cell subsets, and 2),
determine the function of CD4+ T cell DEPTOR in long-term allograft survival. Collectively, these innovative
studies will have broad scientific and biological implications of great significance and relevance to
transplantation immunobiology.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Advancing Transplantation Outcomes in Children
-
批准号:10282915
-
项目类别:
-
资助金额:$234.14万
-
财政年份:2021
-
负责人:David M. Briscoe
-
依托单位:
Advancing Transplantation Outcomes in Children
-
批准号:10483207
-
项目类别:
-
资助金额:$244.19万
-
财政年份:2021
-
负责人:David M. Briscoe
-
依托单位:
Advancing Transplantation Outcomes in Children
-
批准号:10647772
-
项目类别:
-
资助金额:$262.35万
-
财政年份:2021
-
负责人:David M. Briscoe
-
依托单位:
Neuropilin-2 in Alloimmunity
-
批准号:10577824
-
项目类别:
-
资助金额:$50.9万
-
财政年份:2020
-
负责人:David M. Briscoe
-
依托单位:
Neuropilin-2 in Alloimmunity
-
批准号:10355442
-
项目类别:
-
资助金额:$50.9万
-
财政年份:2020
-
负责人:David M. Briscoe
-
依托单位:
Role of DEPTOR in T Cell Activation and Alloimmunity
-
批准号:10302288
-
项目类别:
-
资助金额:$57.53万
-
财政年份:2017
-
负责人:David M. Briscoe
-
依托单位:
Intragraft DepTOR and transplant rejection
-
批准号:9331928
-
项目类别:
-
资助金额:$22.13万
-
财政年份:2017
-
负责人:David M. Briscoe
-
依托单位:
Function of DepTOR in T Cell Activation and Alloimmunity
-
批准号:8785808
-
项目类别:
-
资助金额:$21.98万
-
财政年份:2014
-
负责人:David M. Briscoe
-
依托单位:
Vascular Endothelial Growth Factor Receptor Interactions and Allograft Rejection
-
批准号:8239118
-
项目类别:
-
资助金额:$49.9万
-
财政年份:2011
-
负责人:David M. Briscoe
-
依托单位:
Role of T cell Specific Adaptor Protein in Alloimmunity
-
批准号:8190975
-
项目类别:
-
资助金额:$21.71万
-
财政年份:2011
-
负责人:David M. Briscoe
-
依托单位:
Role of T cell Specific Adaptor Protein in Alloimmunity
-
批准号:8318083
-
项目类别:
-
资助金额:$26.1万
-
财政年份:2011
-
负责人:David M. Briscoe
-
依托单位:
Vascular Endothelial Growth Factor Receptor Interactions and Allograft Rejection
-
批准号:8580190
-
项目类别:
-
资助金额:$51.99万
-
财政年份:2011
-
负责人:David M. Briscoe
-
依托单位:
Vascular Endothelial Growth Factor Receptor Interactions and Allograft Rejection
-
批准号:8960323
-
项目类别:
-
资助金额:$66.61万
-
财政年份:2011
-
负责人:David M. Briscoe
-
依托单位:
Vascular Endothelial Growth Factor Receptor Interactions and Allograft Rejection
-
批准号:8385531
-
项目类别:
-
资助金额:$47.88万
-
财政年份:2011
-
负责人:David M. Briscoe
-
依托单位:
NOVEL IN VIVO MODEL OF CHRONIC ALLOGRAFT REJECTION
-
批准号:8116409
-
项目类别:
-
资助金额:$26.03万
-
财政年份:2010
-
负责人:David M. Briscoe
-
依托单位:
Angiogenesis and Chronic Rejection
-
批准号:8093958
-
项目类别:
-
资助金额:$33.37万
-
财政年份:2010
-
负责人:David M. Briscoe
-
依托单位:
NOVEL IN VIVO MODEL OF CHRONIC ALLOGRAFT REJECTION
-
批准号:7983388
-
项目类别:
-
资助金额:$21.47万
-
财政年份:2010
-
负责人:David M. Briscoe
-
依托单位:
VASCULAR ENDOTHELIAL GROWTH FACTOR IN ALLOIMMUNITY
-
批准号:6919117
-
项目类别:
-
资助金额:$40.5万
-
财政年份:2003
-
负责人:David M. Briscoe
-
依托单位:
VASCULAR ENDOTHELIAL GROWTH FACTOR IN ALLOIMMUNITY
-
批准号:7078622
-
项目类别:
-
资助金额:$39.55万
-
财政年份:2003
-
负责人:David M. Briscoe
-
依托单位:
VASCULAR ENDOTHELIAL GROWTH FACTOR IN ALLOIMMUNITY
-
批准号:6781893
-
项目类别:
-
资助金额:$40.5万
-
财政年份:2003
-
负责人:David M. Briscoe
-
依托单位:
海外基金